Capsaicin induced Inflammatory Pain Model Development Service
Are you currently facing long drug development cycles, challenges in validating preclinical pain models, or difficulty in identifying effective analgesic candidates? Our capsaicin-induced inflammatory pain model development service helps you accelerate drug discovery, obtain highly translational preclinical data, and identify potent analgesic candidates through robust and highly translational preclinical models, comprehensive behavioral and biomarker assessments, and expert scientific guidance.
The global burden of pain necessitates continuous innovation in analgesic drug development. Despite existing therapies, many patients endure chronic and acute pain, underscoring a significant unmet medical need. The capsaicin-induced inflammatory pain model development service at Creative Biolabs provides a critical preclinical tool to address this challenge. By leveraging the well-understood mechanism of capsaicin, we offer a highly relevant and reproducible model that accelerates the identification and validation of novel pain therapeutics.
How Our Capsaicin-Induced Inflammatory Pain Model Development Service Can Assist Your Project?
At CBL, our capsaicin-induced inflammatory pain model development service is meticulously designed to provide you with precise, actionable data crucial for advancing your analgesic drug discovery programs. We deliver robust preclinical efficacy data, critical insights into your compound's mechanism of action, and ultimately, accelerated decision-making for your pipeline. Our solutions are grounded in scientific rigor and tailored to meet the specific demands of your project.
Discover How We Can Help - Request a Consultation.
Workflow
Our comprehensive workflow is designed for clarity, efficiency, and scientific excellence, ensuring a seamless process from project initiation to final data delivery.
- Required Starting Materials: To initiate your study, clients typically provide their test compounds (e.g., purified small molecules, biologics, or natural product extracts), detailed compound administration information (including desired dose ranges, routes of administration, and frequency), and specific research questions or objectives for the study.
- Final Deliverables: Upon completion of the service, you will receive a comprehensive Study Report detailing all experimental procedures, results, statistical analyses, and scientific interpretation. This includes raw data files in an easily accessible format, and a professional presentation of key findings, ready for your internal reviews or external submissions.
- Estimated Timeframe: The typical timeframe for a standard capsaicin-induced inflammatory pain model study ranges from 4 to 8 weeks, depending on the complexity of the study design, the number of test compounds, and the specific endpoints required.
Why Choose Us?
Choosing CBL for your capsaicin-induced inflammatory pain model development needs means partnering with a leader in preclinical pain research. Our distinct advantages ensure your project benefits from unparalleled scientific rigor, efficiency, and a commitment to accelerating your therapeutic breakthroughs.
- Two Decades of Expertise: With over 20 years of experience in preclinical biology, CBL possesses a deep understanding of pain pathophysiology and drug discovery, enabling us to design and execute studies with precision and insight.
- Comprehensive Assessment Capabilities: Beyond standard behavioral assays, we offer advanced molecular and histological analyses, providing a holistic view of your compound's effects on inflammatory pathways and tissue changes.
- Highly Translational Models: Our models are designed to closely mimic human pain conditions, increasing the likelihood of successful translation from preclinical findings to clinical efficacy.
- Customizable Solutions: We understand that every project is unique. Our services are highly flexible, allowing us to tailor study designs to your specific compound, target, and research questions.
- Unwavering Ethical Standards: All studies are conducted in strict adherence to the highest ethical guidelines for animal welfare, ensuring reliable and reproducible results while maintaining scientific integrity.
Capsaicin-Induced Inflammatory Pain Model
Our capsaicin-induced inflammatory pain model offers several distinct advantages, making it an invaluable tool for early-stage analgesic drug discovery:
Application | Description |
High Translational Relevance | By directly activating TRPV1, a well-validated target in human pain pathways and a key player in both somatic and visceral nociceptive systems, this model closely mimics the neurogenic and inflammatory components of various clinical pain states. It provides a physiologically relevant platform to assess the efficacy of compounds targeting TRPV1 or downstream pain signaling pathways, and is ideal for studying both nociceptive pathways and inflammatory responses for pain management therapy development. |
Acute and Reproducible Pain Induction | The model typically involves a single, local administration of capsaicin (e.g., intraplantar injection into the hindpaw of rodents). This reliably induces a rapid, acute inflammatory response and highly reproducible hyperalgesic (increased sensitivity to painful stimuli) and allodynic (pain from non-painful stimuli) behaviors. The acute nature allows for swift evaluation of test articles. |
Robust and Reliable Data | The low variability inherent in the capsaicin model enables statistically significant results with relatively small group sizes, optimizing resource utilization and accelerating decision-making in your drug development process. |
Complementary to Diverse Pain Research | While excellent as a standalone acute inflammatory pain model, it also complements other established models such as the Formalin or Carrageenan models, providing a broader understanding of your compound's analgesic profile across different pain etiologies. |
Validated with Known Analgesics | The capsaicin-induced pain response is reliably attenuated by known analgesic agents, including opioids like morphine, providing a strong internal validation for the model's predictive capacity. |
Mechanism-Based Screening | For compounds specifically designed to modulate TRPV1 activity (e.g., antagonists), this model offers a direct and efficient screening platform to confirm target engagement and evaluate therapeutic potential. |
What We Can Offer
At CBL, our commitment to your success is reflected in the comprehensive range of services and capabilities we bring to your capsaicin-induced inflammatory pain model development service project. We offer:
- Customized Study Design: Tailored protocols developed in close collaboration with your team to align precisely with your unique research objectives, compound characteristics, and specific pain indications.
- Precision Model Execution: Highly skilled scientists and technicians ensure meticulous capsaicin administration and consistent experimental conditions, guaranteeing reliable and reproducible pain induction.
- Comprehensive Behavioral Phenotyping: A full suite of validated behavioral assays, including mechanical, thermal, and cold sensitivities, as well as spontaneous pain behaviors, to accurately quantify analgesic efficacy.
- In-depth Mechanistic Insights: Robust molecular analyses (e.g., cytokine quantification via qPCR and Western blot) and detailed histological examinations to uncover the underlying anti-inflammatory and pain-modulating mechanisms of your compounds.
- Expert Data Interpretation & Reporting: Detailed reports featuring clear data visualization, rigorous statistical analysis, and expert scientific interpretation, providing actionable insights to guide your critical go/no-go decisions.
- Flexible Endpoint Selection: The ability to customize and integrate a wide array of endpoints, from basic pain behaviors to advanced molecular and cellular analyses, ensuring the most relevant data for your specific research questions.
- Unwavering Quality & Ethical Standards: All studies are conducted under strict adherence to international ethical guidelines and our internal quality assurance protocols, ensuring data integrity, reproducibility, and compliance for regulatory submissions.
Related Services
To further support your analgesic drug discovery and development efforts, CBL offers a suite of complementary services and models:
- Chronic Inflammatory Disease Models
- Neuropathic Pain Models
- Custom Assay Development
- Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
Ready to discuss your next project or learn more about how our capsaicin-induced inflammatory pain model development service can benefit your research? Our expert team is ready to assist you.
Contact Our Team for More Information and to Discuss Your Project.
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Green Fluorescent Alpha-synuclein Cell Line (Cat#: NCL2110P209)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)